IP Library Granted Patent US 9,624,470
Granted Patent B2
US 9,624,470 · App. 13/194,623 · Granted Apr 18, 2017

Multipotent lymphohematopoietic progenitor cells

Inventors: Igor I. Slukvin (Verona, WI); Maksym A. Vodyanyk (Madison, WI); James A. Thomson (Madison, WI)
Assignee: Wisconsin Alumni Research Foundation
C12N5/0647C12N2502/1394C12N2506/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,624,470
App. No.
13/194,623
Granted
Apr 18, 2017
Kind
B2
Abstract

This invention relates to hematopoietic precursors derived from human embryonic stem cells. In the culture of differentiated cells from human ES cells, the fully committed hematopoietic precursors are CD34+ and CD43+ but not CD45+. If the cells are cultured until they express CD45, then the cells lose the ability to produce differentiated cells of the lymphoid lineages.

Claims (13)

1. A purified population of CD34+ CD43+ CD45+ CD41 a− CD235a− cells, wherein the cells are prepared by a method comprising:

(a) preparing a culture of macrophage colony-stimulating factor (M-CSF) deficient stromal cells;

(b) adding human embryonic stem (ES) cells to said culture in medium supplemented with serum;

(c) culturing said ES cells until the culture begins to express CD45;

(d) isolating cells that are both CD34+ cells and CD43+ from the resulting culture; and

(e) separating CD45+ CD41 a− CD235a− cells from the isolated cells of step (d), wherein greater than 95% of the cells separated in (e) are CD34+ CD43+ CD45+ CD41 a− CD235a− cells.

2. A cell culture comprising the purified population of cells of claim 1 .

3. A method for generating a population of CD34+ CD43+ CD45+ cells comprising the steps of:

(a) preparing a culture of macrophage colony-stimulating factor (M-CSF) deficient stromal cells;

(b) adding human ES cells to said culture in medium supplemented with serum;

(c) culturing said ES cells until the culture begins to express CD45;

(d) isolating cells that are both CD34+ and CD43+ cells; and

(e) separating CD45+ CD41 a− CD235a− cells from the isolated cells of step (d), wherein greater than 95% of the cells separated in (f) are CD34+ CD43+ CD45+ CD41 a− CD235a− cells.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 27, 2018
From: SLUKVIN, IGOR; VODYANYK, MAKSYM; THOMSON, JAMES
To: WISCONSIN ALUMNI RESEARCH FOUNDATION
Reel/Frame 045052/0015 →
CONFIRMATORY LICENSE Recorded Nov 23, 2011
From: WISCONSIN ALUMNI RESARCH FOUNDATION
To: US ARMY, SECRETARY OF THE ARMY
Reel/Frame 027280/0944 →
Continuity (3)
Division 11520871 · Sep 14, 2006
Provisional Application 60717168 · Sep 15, 2005
Related Publication 20120040362A1 · Feb 16, 2012